Development and application of a high-throughput formulation screening strategy for oral administration in drug discovery

Future Medicinal Chemistry

Volumn 2, Issue 9, 2010, Pages 1391-1398

  Gopinathan, Suma ^a   Nouraldeen, Amr ^a   Wilson, Alan G E ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; MEDICAL DECISION MAKING; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG DISCOVERY;

EID: 77956609919     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.204     Document Type: Review

References (20)

1. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery-a review. Pharmaceut. Sci. Technol. Today 3, 138-145 (2000).
2. Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat. Drug Deliv. Formul. 3, 162-173 (2009).
3. Singh BN, Kim KH. Drug delivery: oral route. Encyclopedia of Pharmaceutical Technology (Third Edition). 1242-1265 (2006).
4. Maas J, Kamm W, Hauck G. An integrated early formulation strategy-from hit evaluation to preclinical candidate profling. Eur. J. Pharm. Biopharm. 66, 1-10 (2007).
5. Neervannan N. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metabol Toxicol. 2, 715-731 (2006).
6. Li P, Zhao L. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19 (2007).
7. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89, 145-154 (2000).
8. Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253, 111-119 (2003).
9. Gonzalez RCB, Huwyler J, Walter I, Mountfeld R, Bittner B. Improved oral bioavailability of cyclosporin A in male Wistar rats: comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int. J. Pharm. 245, 143-151 (2002).
10. Klein S, Wempe MF, Zoeller T et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-P-cyclodextrin. J. Pharm. Pharmacol. 61, 23-30 (2009).
11. Li P, Vishnuvajjala R, Tabibi SE, Yalkowsky SH. Evaluation of in vitro precipitation methods. J. Pharm. Sci. 87, 196-199 (1998).
12. Irwin WJ, Iqbal M. Bropirimine formulation: the dynamic testing of injections. Int. J. Pharm. 83, 241-249 (1992).
13. Ward GH, Yalkowsky SH. Studies in phlebitis. IV: injection rate and amiodarone-induced phlebitis. J. Parenter. Sci. Technol. 47, 40-43 (1993).
14. Ward GH, Yalkowsky SH. Studies in phlebitis. VI: dilution-induced precipitation of amiodarone HCl. J. Parenter. Sci. Technol. 47, 161-165 (1993).
15. Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H. Nonclinical vehicle use in studies by multiple routes in multiple species. Int. J. Toxicol. 25, 499-521 (2006).
16. Pestel S, Martin H-J, Maier G-M, Guth B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J. Pharmacol. Toxicol. Methods 54, 200-214 (2006).
17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001). (Pubitemid 33653411)
18. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230 (2004).
19. Ghose AK, Crippen G M. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships I. Partition coeffcients as a measure of hydrophobicity. J. Comput. Chem. 7, 565-577 (1986)
20. Sarawek S, Li L, Yu X-Q et al. Examination of the utility of the high throughput in vitro metabolic stability assay to estimate in vivo clearance in the mouse. Open Drug Metabol. J. 3, 31-42 (2009).